AR065947A1 - Antagonistas de los receptores de la hormona liberadora de gonadodropina (gnrh) - Google Patents

Antagonistas de los receptores de la hormona liberadora de gonadodropina (gnrh)

Info

Publication number
AR065947A1
AR065947A1 ARP080101410A ARP080101410A AR065947A1 AR 065947 A1 AR065947 A1 AR 065947A1 AR P080101410 A ARP080101410 A AR P080101410A AR P080101410 A ARP080101410 A AR P080101410A AR 065947 A1 AR065947 A1 AR 065947A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
independently
heterocycle
occurrence
Prior art date
Application number
ARP080101410A
Other languages
English (en)
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of AR065947A1 publication Critical patent/AR065947A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen composiciones que contienen un compuesto de esta invencion de combinacion con un portador farmacéuticamente aceptable y el uso de los mismos para preparar medicamentos. Enfermedades derivadas de la regulacion hipofisaria de losesteroides gonadales, como disfunciones sexuales en mujeres y hombres. Reivindicacion 1: Un compuesto que tiene la siguiente estructura (1) y estereoisomeros, ésteres, solvatos y sales farmacéuticamente aceptables del mismo, en el que: A espiridilo, fenilo, quinolinilo, naftiridinilo, tienopirimidinilo o 2-oxo-pirimidinilo, en el que el piridilo, fenilo, quinolinilo, tienopirimidinilo o 2-oxo-pirimidinilo está sustituido con 0-5 R4; R1a es H, halogeno, alquilo C1-4, alcoxilo C1-4 otrifluorometilo; R1b y R1c son iguales o diferentes y son independientemente H, halogeno, hidroxilo, haloalquilo C1-4, -alquil C1-6-(R5)p, O-alquil C1-6-(R5)p, -alquil C1-6-O-alquil C1-6-(R5)p, -NR7-alquil C1-6-(R5)p o -S(O)m-alquil C1-6-(R5)p; R1des F, Cl, metilo, CF3 o ciano; R2 es alquil C1-4-(R5)p; R2a es fenilo sustituido con 0-4 R3, heteroarilo sustituido con 0-4 R3, alquilo C1-6 sustituido con 0-4 R3, arilalquilo C1-4 sustituido con 0-4 R3o heteroarilalquilo C1-4 sustituido con 0-4 R3;o R2 y r2a tomados junto con el nitrogeno al que están unidos forman un heterociclo que está sustituido con 0-4 R3; R3 en cada aparicion es independientemente halogeno, ciano, haloalquilo C1-4, R5, -alquil C1-6-(R5)p, -alquil C1-6-O-alquil C1-6-(R5)p, -O-alquil C1-6-(R5)p, -NR7-alquil C1-6-(R5)p, -S(O)m-alquil C1-6-(R5)p, -O-alquil C1-6NR7-alquil C1-6-(R5)p, heterociclo-(R5)p; R4 en cada aparicion es independientemente halogeno, alquilo C1-6, haloalquilo C1-4, alcoxilo C1-6, hidroxilo,ciano, tioalquilo C1-6, -C(O)NR7R8 o heteroarilo de 5 miembros; R5 en cada aparicion es independientemente H, hidroxilo, -OC(O)-alquilo C1-6, -OC(O)O-alquilo C1-6, -OC(O)-alquil C1-6-NR7R8, -COOR6, -C(O)NR7R8, -NR7C(O)NR7R8, -S(O)2NR9R9, -S(O)m-alquilo C1-4, -NR7R8, alcoxilo C1-6, -O-heterociclo, o heterociclo en el que dicho heterociclo y dicho -O-heterociclo están sustituidos con 0-4 grupos seleccionados de halogeno, alquilo C1-6, haloalquilo C1-4, hidroxilo, oxo, tio, -NH2, -S(O)2alquilo C1-4 y -COOH; R6 en cada aparicion es independientemente H, alquilo C1-4, alquil C1-4-O-C(O)-alquilo C1-6 o alquil C1-4-O-C(O)-O-alquilo C1-6; R7 en cada aparicion es independientemente H, alquilo C1-4, hidroxilo o heterociclo en el quedicho heterociclo está sustituido con 0-4 frupos seleccionados de halogeno, alquilo c1-6, hidroxilo, ceto, -NH2 y -COOH; R8 en cada aparicion es independientemente H, alquilo C1-4, haloalquilo C1-4, -C(O)-alquilo C1-4, -C(O)-haloalquilo C1-4, -S(O)m-haloalquilo C1-4 o -S(O)m-alquilo C1-4; R9 en cada aparicion es independientemente H, alquilo C1-4 o C(O)alquilo C1-4; m es 0-2; y p en cada aparicion es independientemente 1-3.
ARP080101410A 2007-04-06 2008-04-04 Antagonistas de los receptores de la hormona liberadora de gonadodropina (gnrh) AR065947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91061907P 2007-04-06 2007-04-06

Publications (1)

Publication Number Publication Date
AR065947A1 true AR065947A1 (es) 2009-07-15

Family

ID=39731245

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101410A AR065947A1 (es) 2007-04-06 2008-04-04 Antagonistas de los receptores de la hormona liberadora de gonadodropina (gnrh)

Country Status (8)

Country Link
US (2) US8263588B2 (es)
AR (1) AR065947A1 (es)
CL (1) CL2008000986A1 (es)
PA (1) PA8775701A1 (es)
PE (1) PE20090236A1 (es)
TW (1) TW200845974A (es)
UY (1) UY31008A1 (es)
WO (1) WO2008124614A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008000985A1 (es) 2007-04-06 2008-10-10 Neurocrine Biosciences Inc Compuesto derivado de heterociclos de nitrogeno, agonistas del receptor gnrh; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar una afeccion relacionada con las hormonas sexuales, endometriosis, dismenorrea, enfermedad de ov
EP3263568B1 (en) * 2011-07-18 2021-08-25 Merck Patent GmbH Benzamides

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826833A (en) * 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
JPH03173865A (ja) 1988-11-11 1991-07-29 Banyu Pharmaceut Co Ltd 置換アリルアミン誘導体、その製造法及びその用途
US5082849A (en) * 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
KR920702353A (ko) 1990-06-29 1992-09-03 로버트 에이. 아미테이지 아테롬성 동맥경화증 및 혈전등 치료제인 2-아미노-6-페닐-4h-피란-4-온
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DK0638071T3 (da) * 1992-12-28 1997-10-27 Eisai Co Ltd Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR)
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
EP0778845A1 (de) 1994-09-02 1997-06-18 Novartis AG Oligonukleotidkonjugate, zusammensetzungen und verfahren zur spaltung von ribonukleinsäuren
DE4439332A1 (de) * 1994-11-04 1996-05-09 Bayer Ag Substituierte Azolylsulfonylphenyluracile
ES2300119T3 (es) * 1997-02-27 2008-06-01 Takeda Pharmaceutical Company Limited Compuestos de amina, su produccion y su uso como inhibidores de la produccion de beta-amiloide.
GB9707830D0 (en) 1997-04-18 1997-06-04 Smithkline Beecham Plc Novel compounds
NZ501258A (en) 1997-07-11 2001-07-27 Smithkline Beecham P Benzenesulfonamide compounds with 5HT6 receptor antagonist activity for treating anxiety and/or depression
US6258822B1 (en) * 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
AU3665199A (en) 1998-04-29 1999-11-16 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
FR2779963A1 (fr) * 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
US6635657B1 (en) * 1998-12-23 2003-10-21 Eli Lilly And Company Aromatic amides
EP1185530A1 (en) 1999-05-14 2002-03-13 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
KR20020045609A (ko) 1999-10-15 2002-06-19 추후기재 고나도트로핀-분비 호르몬 수용체 길항제 및 이와 관련된방법
JP4931314B2 (ja) 2000-01-25 2012-05-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプタアンタゴニストおよびそれに関連した方法
DE60141871D1 (de) * 2000-05-05 2010-06-02 Wallac Oy Oligonukleotidmarkierungsstoffe und ihre Verwendung
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
HUP0303497A3 (en) 2000-10-18 2006-02-28 Pfizer Prod Inc Pharmaceutical compositions containing combination of statins and sorbitol dehydrogenase inhibitors
IL155202A0 (en) 2000-10-20 2003-11-23 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
JP4342178B2 (ja) * 2001-04-06 2009-10-14 バイオクリスト・ファマシューティカルズ インク． セリンプロテアーゼ阻害剤としてのビアリール化合物
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
EP1412363A1 (en) 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists
JP2005505525A (ja) 2001-08-02 2005-02-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
EP1411941A2 (en) 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
KR20050029209A (ko) 2002-07-15 2005-03-24 미리어드 제네틱스, 인크. 화합물, 조성물 및 이의 사용방법
ATE454378T1 (de) 2002-11-01 2010-01-15 Vertex Pharma Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
AU2003287878A1 (en) 2002-12-11 2004-06-30 7Tm Pharma A/S Quinoline compounds for use in mch receptor related disorders
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US8178570B2 (en) 2003-04-09 2012-05-15 Exelixis, Inc. Tie-2 modulators and methods of use
EP1631560A2 (en) 2003-04-25 2006-03-08 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
CN100424078C (zh) 2003-07-07 2008-10-08 纽罗克里生物科学有限公司 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物
CN100376246C (zh) 2003-07-07 2008-03-26 纽罗克里生物科学有限公司 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物
WO2005007633A1 (en) 2003-07-07 2005-01-27 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
ATE412642T1 (de) 2003-07-25 2008-11-15 Novartis Ag Inhibitoren von p-38-kinase
CA2536313A1 (en) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
AR046698A1 (es) 2003-11-11 2005-12-21 Ishihara Sangyo Kaisha Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo
RU2006123704A (ru) * 2003-12-05 2008-01-20 Берингер Ингельхайм Фармасьютиклз, Инк. (Us) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ АМИДО 3-АМИНОТИЕНО[2, 3-b]ПИРИДИН-2-КАРБОНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ IKK
WO2005067502A2 (en) * 2004-01-02 2005-07-28 Merck & Co., Inc. Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
WO2006078287A2 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
US7683097B2 (en) 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
WO2006000358A1 (de) 2004-06-25 2006-01-05 Basf Aktiengesellschaft 2, 4, 5, 6-substituierte pyridine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
WO2006017214A2 (en) 2004-07-12 2006-02-16 Merck & Co., Inc. Inhibitors of histone deacetylase
KR20140048343A (ko) 2004-09-02 2014-04-23 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
AU2005293384A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as B Raf inhibitors
EP1802606B1 (en) 2004-10-19 2011-03-16 Compass Pharmaceuticals LLC Arylcarboxamides and their use as anti-tumor agents
WO2006083005A1 (ja) * 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
WO2006094237A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
CA2610659A1 (en) 2005-06-14 2006-12-21 Merck Frosst Canada Ltd. Reversible inhibitors of monoamine oxidase a and b
PL1939204T6 (pl) * 2005-10-19 2024-03-25 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja oraz jej zastosowanie medyczne
CL2008000985A1 (es) * 2007-04-06 2008-10-10 Neurocrine Biosciences Inc Compuesto derivado de heterociclos de nitrogeno, agonistas del receptor gnrh; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar una afeccion relacionada con las hormonas sexuales, endometriosis, dismenorrea, enfermedad de ov

Also Published As

Publication number Publication date
US8507536B2 (en) 2013-08-13
US8263588B2 (en) 2012-09-11
TW200845974A (en) 2008-12-01
CL2008000986A1 (es) 2008-10-17
PA8775701A1 (es) 2009-04-23
UY31008A1 (es) 2008-11-28
WO2008124614A1 (en) 2008-10-16
PE20090236A1 (es) 2009-03-13
US20130040975A1 (en) 2013-02-14
US20100184741A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
AR065948A1 (es) Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
AR012825A1 (es) Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos
AR069494A1 (es) Derivados de acidos fosfonicos
AR051461A1 (es) Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR074024A1 (es) Compuesto de arilazol-2-il-cianoetilamino enantiomericamente enriquecidos, composicion plaguicida y su uso para prevenir la infeccion parasitaria
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
PE20160173A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO
AR038834A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR078674A1 (es) Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas
AR094840A1 (es) Pirazoles fungicidas
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
AR035371A1 (es) Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
RU2009113612A (ru) Ацетамидные производные хиназолинона и изохинолинона
AR059516A1 (es) Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas
AR075597A1 (es) Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas .
AR048495A1 (es) Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk
ECSP066947A (es) Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
AR071300A1 (es) Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento
AR068734A1 (es) Esteroides con actividad agonista del receptor de glucocorticoides
AR106100A1 (es) Compuestos bicíclicos como inhibidores duales atx / ca

Legal Events

Date Code Title Description
FB Suspension of granting procedure